Safety, efficacy and immunogenicity of concomitant molecular target drug or cytokine therapy and autologous tumor lysate-pulsed dendritic cell therapy in patients with advanced renal cell carcinoma
Not Applicable
- Conditions
- Renal cell carcinoma
- Registration Number
- JPRN-UMIN000014703
- Lead Sponsor
- The University of Tokyo Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who have: - Pulmonary fibrosis or interstitial pneumonia, or history or predisposition of them; - Serious drug allergy; - Active infections; - Serious cardiac disease; - Active autoimmune diseases; - Continuous systemic administration of steroids within 4 weeks; - Other currently active malignancies; - Women during pregnancy, possible pregnancy, or breast-feeding; - Brain metastases;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method